Who is sponsoring NCT07104799?

NCT07104799 is sponsored by Massachusetts General Hospital.

What condition does NCT07104799 study?

NCT07104799 studies Myelofibrosis, Hematopoietic Cell Transplantation (HCT).

What is the status of NCT07104799?

NCT07104799 is currently RECRUITING.

Last reviewed 2026-03-30 · How we verify

A Phase I Study to Evaluate the Safety and Maximum Tolerated Dose of Momelotinib Durind and Following Hematopoietic Cell Transplantation for Patients With Myelofibrosis

NCT07104799 Phase 1 RECRUITING

This is a single-center, open-label, phase I study to determine the safety and tolerability of momelotinib in patients with myelofibrosis during and after hematopoietic cell transplantation (HCT).

Details

Lead sponsor	Massachusetts General Hospital
Phase	Phase 1
Status	RECRUITING
Enrolment	28
Start date	2026-02-23
Completion	2030-01

Conditions

Myelofibrosis
Hematopoietic Cell Transplantation (HCT)

Interventions

Momelotinib

Primary outcomes

Maximum Tolerated Dose (MTD) of Momelotinib — From start of study treatment (Day -7) through 28 days.
MTD is defined as the highest dose level at which 0 or 1 of 6 patients experience a Dose Limiting Toxicity (DLT). Toxicities will be graded and documented according to NCI CTCAE version 5.0.

Countries

United States